JP2012510512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510512A5 JP2012510512A5 JP2011539506A JP2011539506A JP2012510512A5 JP 2012510512 A5 JP2012510512 A5 JP 2012510512A5 JP 2011539506 A JP2011539506 A JP 2011539506A JP 2011539506 A JP2011539506 A JP 2011539506A JP 2012510512 A5 JP2012510512 A5 JP 2012510512A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- hdac2
- formula
- composition
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 24
- 230000002401 inhibitory effect Effects 0.000 claims 24
- 102100016432 HDAC2 Human genes 0.000 claims 19
- 101700061787 HDAC2 Proteins 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 206010001897 Alzheimer's disease Diseases 0.000 claims 5
- 102100002572 HDAC1 Human genes 0.000 claims 5
- 101700036927 HDAC1 Proteins 0.000 claims 5
- 125000002015 acyclic group Chemical group 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 3
- 102100013102 HDAC10 Human genes 0.000 claims 3
- 101710042173 HDAC10 Proteins 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 230000007787 long-term memory Effects 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 210000001218 Blood-Brain Barrier Anatomy 0.000 claims 2
- 230000007067 DNA methylation Effects 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- XSVMFMHYUFZWBK-NSHDSACASA-N EXELON Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 2
- 101700049063 FUS3 Proteins 0.000 claims 2
- 102100016431 HDAC3 Human genes 0.000 claims 2
- 101700081813 HDAC3 Proteins 0.000 claims 2
- 229960001685 Tacrine Drugs 0.000 claims 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N Tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 2
- 125000005418 aryl aryl group Chemical group 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 229960003530 donepezil Drugs 0.000 claims 2
- 125000005842 heteroatoms Chemical group 0.000 claims 2
- 230000015654 memory Effects 0.000 claims 2
- 229960004136 rivastigmine Drugs 0.000 claims 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- KQYVZLXCACFZRW-UHFFFAOYSA-N 1,2-dihydropyrimidin-6-amine Chemical compound NC1=CC=NCN1 KQYVZLXCACFZRW-UHFFFAOYSA-N 0.000 claims 1
- IDYKCXHJJGMAEV-RRKCRQDMSA-N 4-amino-5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 IDYKCXHJJGMAEV-RRKCRQDMSA-N 0.000 claims 1
- STRZQWQNZQMHQR-UAKXSSHOSA-N 5-fluorocytidine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 STRZQWQNZQMHQR-UAKXSSHOSA-N 0.000 claims 1
- LJIRBXZDQGQUOO-KVTDHHQDSA-N 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LJIRBXZDQGQUOO-KVTDHHQDSA-N 0.000 claims 1
- LAOLDMMWVYDDID-KVQBGUIXSA-N 6-amino-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 LAOLDMMWVYDDID-KVQBGUIXSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 229940039856 Aricept Drugs 0.000 claims 1
- 229960002756 Azacitidine Drugs 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- 229940108366 Exelon Drugs 0.000 claims 1
- 229960003980 Galantamine Drugs 0.000 claims 1
- 102100007188 HDAC5 Human genes 0.000 claims 1
- 101700054126 HDAC5 Proteins 0.000 claims 1
- 102100007189 HDAC6 Human genes 0.000 claims 1
- 101700002249 HDAC6 Proteins 0.000 claims 1
- 102100007195 HDAC7 Human genes 0.000 claims 1
- 101700004675 HDAC7 Proteins 0.000 claims 1
- 101700005838 HDAC9 Proteins 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 108020004388 MicroRNAs Proteins 0.000 claims 1
- 229920000272 Oligonucleotide Polymers 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N Procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 claims 1
- 230000025458 RNA interference Effects 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 108020004459 Small Interfering RNA Proteins 0.000 claims 1
- 229920001891 Small hairpin RNA Polymers 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- RPQZTTQVRYEKCR-WCTZXXKLSA-N Zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000004888 barrier function Effects 0.000 claims 1
- 230000003727 cerebral blood flow Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003412 degenerative Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 230000036545 exercise Effects 0.000 claims 1
- 230000003340 mental Effects 0.000 claims 1
- 229920001239 microRNA Polymers 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960000244 procainamide Drugs 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 229920002033 ribozyme Polymers 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 230000000946 synaptic Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 229960005486 vaccines Drugs 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 201000004810 vascular dementia Diseases 0.000 claims 1
Claims (19)
- HDAC2阻害剤を含む、対象における記憶を増強するための組成物。
- HDAC2阻害剤が、選択的HDAC2阻害剤である、請求項1に記載の組成物。
- 記憶が長期記憶であるか、または、対象が長期記憶へのアクセスの低下を有し、および/または、組成物が、対象におけるシナプスネットワークを再構築するか、または記憶を取り戻させる、請求項1または2に記載の組成物。
- 長期記憶が損傷しており、長期記憶の損傷が加齢によるもの、または、傷害によるものである、請求項3に記載の組成物。
- HDAC2阻害剤が、i)HDAC1阻害剤ではないか、または、ii)HDAC5、HDAC6、HDAC7またはHDAC10阻害剤ではない、請求項1〜4のいずれか一項に記載の組成物。
- 選択的HDAC2阻害剤が、siRNA、shRNA、miRNA、dsRNAまたはリボザイムなどのHDAC2 RNAiあるいはそれらの変異体である、請求項2に記載の組成物。
- DNAメチル化阻害剤と共に投与され、DNAメチル化阻害剤が、任意に、5−アザシチジン、5−アザ−2’デオキシシチジン、5,6−ジヒドロ−5−アザシチジン、5,6−ジヒドロ−5−アザ−2’デオキシシチジン、5−フルオロシチジン、5−フルオロ−2’デオキシシチジン、および5−アザ−2’デオキシシトシン、5,6−ジヒドロ−5−アザ−2’デオキシシトシン、および5−フルオロ−2’デオキシシトシンを含む短鎖オリゴヌクレオチド、およびプロカインアミド、ゼブラリン、および(−)−エピガロカテキン−3−ガレートからなる群から選択される、請求項1〜6のいずれか一項に記載の組成物。
- 対象が、AMCI(軽度認識障害)、アルツハイマー病、記憶喪失、アルツハイマー病に関連する注意欠陥症状、アルツハイマー病に関連する神経変性、混合血管起源の認知症、変性起源の認知症、初老期認知症、老年性認知症、パーキンソン病に関連する認知症、血管性認知症、進行性核上性麻痺、または大脳皮質基底核変性症からなる群から選択される障害を有している、請求項1または2に記載の組成物。
- 対象が、HDAC2阻害剤の投与の後に認識機能について評価されるか、または、脳血流または脳血液関門機能を評価することにより処置についてモニターされる、請求項1または2に記載の組成物。
- 追加の治療剤と共に投与され、追加の治療剤が、任意に、ARICEPTまたはドネペジル、COGNEXまたはタクリン、EXELONまたはリバスチグミン、REMINYLまたはガランタミン、抗アミロイドワクチン、Aベータ低下治療、頭の体操、または精神的刺激である、請求項8に記載の組成物。
- HDAC2阻害剤を含む、アルツハイマー病を処置するための組成物。
- HDAC2阻害剤が、選択的HDAC2阻害剤、選択的HDAC1/HDAC2阻害剤、選択的HDAC1/HDAC2/HDAC3阻害剤、選択的HDAC1/HDAC2/HDAC10阻害剤、または選択的HDAC1/HDAC2/HDAC3/HDAC10阻害剤である、請求項11に記載の組成物。
- HDAC2阻害剤が、式(IV)
R3は、任意に置換されたアリール、任意に置換されたヘテロアリール、またはアリール−C1〜6アルキレンである、
の化合物であり、式IVが、任意に
- HDAC2阻害剤が、式(VI)
の化合物であり、式VIが、任意に
- HDAC2阻害剤が、式(I)
R3は、アリールまたはヘテロアリールである、
の化合物であり、式Iが、任意に
- HDAC2阻害剤が、式(II)
R3は、アリールまたはヘテロアリールである、
の化合物であり、式IIが、任意に
- HDAC2阻害剤が、式(III)
R1およびR2は、H、置換または非置換、分岐のまたは非分岐の、環式のまたは非環式のC1〜6アルキルから独立して選択され;および
R3は、アルキニル、アリールまたはヘテロアリールである、
の化合物であり、式IIIが、任意に
- HDAC2阻害剤が、式(V)
R3は、アリールまたはヘテロアリールである、
の化合物であり、式Vが、任意に
- HDAC2阻害剤および薬学的に許容可能な担体を含み、脳組織への送達のための処方であるか、または、血液脳関門を横断するように処方されている、医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11969808P | 2008-12-03 | 2008-12-03 | |
US61/119,698 | 2008-12-03 | ||
PCT/US2009/006355 WO2010065117A1 (en) | 2008-12-03 | 2009-12-02 | Inhibition of hdac2 to promote memory |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012510512A JP2012510512A (ja) | 2012-05-10 |
JP2012510512A5 true JP2012510512A5 (ja) | 2013-01-24 |
Family
ID=42233521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011539506A Pending JP2012510512A (ja) | 2008-12-03 | 2009-12-02 | 記憶を推進するためのhdac2の阻害 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120101147A1 (ja) |
EP (1) | EP2367599A4 (ja) |
JP (1) | JP2012510512A (ja) |
CN (1) | CN102271763A (ja) |
AU (1) | AU2009322958B2 (ja) |
CA (1) | CA2745073A1 (ja) |
NZ (1) | NZ593447A (ja) |
WO (1) | WO2010065117A1 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263547B2 (en) | 2008-05-28 | 2012-09-11 | Massachusetts Institute Of Technology | DISC-1 pathway activators in the control of neurogenesis |
AU2010313255B2 (en) * | 2009-10-30 | 2015-04-30 | Massachusetts Institute Of Technology | The use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
EP2598133A4 (en) * | 2010-07-30 | 2014-03-05 | Univ California | METHOD AND THERAPEUTIC SUBSTANCE FOR TREATMENT AND REGULATION OF MEMORY FORMATION |
CN102477001B (zh) * | 2010-11-29 | 2015-07-15 | 江苏先声药物研究有限公司 | 一种苯甲酰胺类组蛋白去乙酰化酶抑制剂 |
EP2712655B1 (en) | 2011-04-28 | 2019-12-18 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
ES2719266T3 (es) | 2011-07-22 | 2019-07-09 | Massachusetts Inst Technology | Activadores de histona desacetilasas de clase I (HDACS), y usos de los mismos |
US20130028956A1 (en) * | 2011-07-29 | 2013-01-31 | Andre Fischer | Method for preventing or treating memory impairment and pharmaceutical compositions useful therefore |
KR101939710B1 (ko) * | 2011-12-21 | 2019-01-17 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
CA2880117C (en) | 2012-07-27 | 2021-04-06 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
WO2014018913A2 (en) * | 2012-07-27 | 2014-01-30 | University Of Connecticut | Santacruzamate a compositions and analogs and methods of use |
WO2014046871A1 (en) * | 2012-09-04 | 2014-03-27 | Massachusetts Institute Of Technology | The use of gene expression profiling as a biomarker for assessing the efficacy of hdac inhibitor treatment in neurodegenerative conditions |
US9914717B2 (en) | 2012-12-20 | 2018-03-13 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
MX2015007862A (es) * | 2012-12-28 | 2016-02-05 | Nippon Zoki Pharmaceutical Co | Derivado de amida del acido cinamico. |
KR101486248B1 (ko) * | 2013-04-29 | 2015-01-27 | 숙명여자대학교산학협력단 | Dna 메틸화 저해제를 포함하는 상염색체 우성 다낭신 개선 또는 치료용 약학 조성물 |
EP2801569A1 (en) | 2013-05-09 | 2014-11-12 | Ikerchem, S.L. | Histone deacetylase inhibitors based on derivatives of tricyclic polyhydroacridine and analogs possessing fused saturated five- and seven-membered rings |
CA2931345A1 (en) * | 2013-11-24 | 2015-05-28 | Taipei Medical University | Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits |
US20170173083A1 (en) * | 2014-03-26 | 2017-06-22 | The Brigham And Women's Hospital, Inc. | Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells |
WO2016134271A1 (en) * | 2015-02-19 | 2016-08-25 | Massachusetts Institute Of Technology | Systems and methods for selective memory enhancement and/or disruption |
ES2944446T3 (es) * | 2015-06-08 | 2023-06-21 | Univ California | Uso de la modulación de H3K9me3 para potenciar la función cognitiva |
US11149062B2 (en) | 2015-08-28 | 2021-10-19 | Uwm Research Foundation, Inc. | HDAC inhibitors and methods of treatment using the same |
US20190015473A1 (en) * | 2017-07-13 | 2019-01-17 | Massachusetts Institute Of Technology | Targeting the hdac2-sp3 complex to enhance synaptic funcation |
CN111630166B (zh) * | 2017-08-10 | 2024-04-19 | 希望之城 | 条件性-siRNA及其在治疗心肌肥大中的用途 |
WO2019235501A1 (ja) * | 2018-06-06 | 2019-12-12 | 塩野義製薬株式会社 | ヒストン脱アセチル化酵素阻害剤 |
WO2020033938A1 (en) | 2018-08-10 | 2020-02-13 | City Of Hope | Programmable conditional sirnas and uses thereof |
US20220153727A1 (en) * | 2019-03-28 | 2022-05-19 | Kaneka Corporation | Method for producing pyrrole-imidazole (poly)amide |
AU2020291460A1 (en) * | 2019-06-13 | 2022-01-20 | Dana-Farber Cancer Institute, Inc. | HDAC3 catalytic inhibitor development and uses thereof |
EP4074700A4 (en) | 2019-12-10 | 2024-02-07 | Shionogi & Co., Ltd | HISTONE DEACETYLASE INHIBITOR HAVING AN AROMATIC HETEROCYCLIC GROUP CONTAINING NITROGEN |
CN110951738B (zh) * | 2019-12-23 | 2021-10-15 | 华南农业大学 | 猪hdac2基因的表达抑制剂及其应用 |
CN112062826A (zh) * | 2020-06-01 | 2020-12-11 | 暨南大学 | 一种与中枢神经衰老相关的乙酰化修饰h2b蛋白标记分子及其应用 |
CN116270932A (zh) * | 2021-12-13 | 2023-06-23 | 南京大学 | 一种具有治疗脑损伤疾病的安宫牛黄丸小rna组合及其应用 |
CN115192714A (zh) * | 2022-07-08 | 2022-10-18 | 沈阳药科大学 | Hdac6抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077591A1 (en) * | 2002-03-28 | 2004-04-22 | The Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease |
US20050054647A1 (en) * | 2002-12-27 | 2005-03-10 | Detlev Schuppan | New pharmaceutical combination |
TW200424174A (en) * | 2003-02-06 | 2004-11-16 | Hoffmann La Roche | New TP diamide |
US20080057529A1 (en) * | 2003-12-18 | 2008-03-06 | Michele Pallaoro | Method for Identifying Histone Deacetylase Inhibitors |
US20060018921A1 (en) * | 2004-07-16 | 2006-01-26 | Baylor College Of Medicine | Histone deacetylase inhibitors and cognitive applications |
EP1817020A4 (en) * | 2004-11-08 | 2012-11-21 | Errant Gene Therapeutics Inc | INHIBITORS OF HISTONATE ACETYLASE |
WO2006122319A2 (en) * | 2005-05-11 | 2006-11-16 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20070078083A1 (en) * | 2005-09-07 | 2007-04-05 | Braincells, Inc. | MODULATION OF NEUORGENESIS BY HDac INHIBITION |
WO2008086452A2 (en) * | 2007-01-10 | 2008-07-17 | Columbia University | Treatment and prevention of alzheimer's disease |
-
2009
- 2009-12-02 US US13/132,179 patent/US20120101147A1/en not_active Abandoned
- 2009-12-02 NZ NZ593447A patent/NZ593447A/xx not_active IP Right Cessation
- 2009-12-02 CA CA2745073A patent/CA2745073A1/en not_active Abandoned
- 2009-12-02 AU AU2009322958A patent/AU2009322958B2/en not_active Ceased
- 2009-12-02 EP EP09830725A patent/EP2367599A4/en not_active Withdrawn
- 2009-12-02 JP JP2011539506A patent/JP2012510512A/ja active Pending
- 2009-12-02 CN CN2009801532239A patent/CN102271763A/zh active Pending
- 2009-12-02 WO PCT/US2009/006355 patent/WO2010065117A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012510512A5 (ja) | ||
JP7189983B2 (ja) | 異常炎症反応に関連する状態を処置するための方法および組成物 | |
RU2016146817A (ru) | Композиции и способы модулирования экспрессии ангиопоэтин-подобного белка 3 | |
JP2019511491A5 (ja) | ||
JP2009280627A5 (ja) | ||
CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
JP2012500197A5 (ja) | ||
JP2009504763A5 (ja) | ||
JP2008533007A5 (ja) | ||
AU2022253068A1 (en) | Thionucleosides as antiviral agents | |
JP2018502956A5 (ja) | ||
WO2009148605A3 (en) | Methods for treating hypercholesterolemia | |
JP2018520189A5 (ja) | ||
EP2455471A3 (en) | Methods for treating hypercholesterolemia | |
JP2012111764A5 (ja) | ||
US20240194304A1 (en) | Prediction Method, Prediction Device, and Prediction Program for New Indication of Desired Known Drug or Equivalent Material Thereof | |
JP2008534520A5 (ja) | ||
JP2014519507A5 (ja) | ||
FR2924713B1 (fr) | Nouveaux derives diazeniumdiolates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2007073560A3 (en) | Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds | |
JP2014523426A5 (ja) | ||
JP2019516726A5 (ja) | ||
JP2005281314A5 (ja) | ||
WO2014100679A8 (en) | Stimulation and enhancement of regeneration of tissues | |
NO20090067L (no) | Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer |